INO Stock Forecast: Inovio Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Inovio Pharmaceuticals, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 49 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Inovio Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
INO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 11 Nov 2026 | Piper Sandler | Reiterates | Overweight | $8.00 → $6.00 |
| 7 Nov 2026 | Jefferies | Maintains | Buy | — |
| 6 Nov 2026 | Jefferies | Maintains | Buy | $3.00 → $8.00 |
| 2 Nov 2026 | HC Wainwright & Co. | Upgrade | Buy | $5.00 |
| 13 Aug 2026 | Jefferies | Upgrade | Buy | $1.80 → $3.00 |
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | $6.00 → $4.00 |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Neutral | $3.00 → $2.50 |
| 14 Nov 2025 | Piper Sandler | Reiterates | Overweight | — |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 July 2025 | Piper Sandler | Initiates | Overweight | — |
| 14 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 14 May 2025 | RBC Capital | Reiterates | Sector Perform | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 19 Mar 2025 | RBC Capital | Maintains | Sector Perform | — |
| 14 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | $18 |
| 13 Jan 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 10 Jan 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 18 Nov 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 18 Nov 2024 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INO.
This page is one stock. Monday covers all of them.
INO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
INO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1085.6×
- Price / book
- 23.3×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 3% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −352.5%
- Return on assets
- −74.9%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Inovio Pharmaceuticals, Inc. has a market value of $320.3M and an enterprise value of $279.2M.
Revenue in the twelve months to 31 Mar 2026: $0.0. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$84.9M.
Free cash flow in the twelve months to 31 Mar 2026: −$83.6M, after $226K of capital spending.
Inovio Pharmaceuticals, Inc. employs 112 people.
Data provided by Twelve Data
INO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at INO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Inovio Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about INO
What is the INO stock price forecast for 2026-2027?
The median 12-month analyst price target for Inovio Pharmaceuticals, Inc. is $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is INO stock a buy right now?
Of the 3 analysts covering Inovio Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inovio Pharmaceuticals, Inc. 49 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INO?
As at 21 Nov 2026, Inovio Pharmaceuticals, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will INO stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $6, and Ticker Nerd's factor model ranks Inovio Pharmaceuticals, Inc. 49 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the INO stock forecast for 2030?
No analyst covering Inovio Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
What does Inovio Pharmaceuticals, Inc. do?
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications.
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.
CEO Dr. Jacqueline E. Shea Ph.D. · 112 employees · United States · https://www.inovio.com